Eton Pharmaceuticals Shares Outstanding History (ETON)
Eton Pharmaceuticals reported 27.0M shares outstanding at the end of fiscal 2025.
View full Eton Pharmaceuticals company overviewEton Pharmaceuticals annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 27.0M | 337,977 | +1.27% |
| 2024 | 2024-12-31 | 26.7M | 1.0M | +3.97% |
| 2023 | 2023-12-31 | 25.7M | 334,943 | +1.32% |
| 2022 | 2022-12-31 | 25.4M | 727,115 | +2.95% |
| 2021 | 2021-12-31 | 24.6M | 313,196 | +1.29% |
| 2020 | 2020-12-31 | 24.3M | 6.4M | +36.00% |
| 2019 | 2019-12-31 | 17.9M | 269,558 | +1.53% |
| 2018 | 2018-12-31 | 17.6M | 11.6M | +193.47% |
| 2017 | 2017-12-31 | 6.0M | — | — |
Eton Pharmaceuticals quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 28.3M | 1.5M | +5.49% |
| Q1 2026 | 2026-03-31 | 27.4M | 542,256 | +2.02% |
| Q4 2025 | 2025-12-31 | 27.0M | 337,977 | +1.27% |
| Q3 2025 | 2025-09-30 | 26.8M | 981,331 | +3.80% |
| Q2 2025 | 2025-06-30 | 26.8M | 1.1M | +4.16% |
| Q1 2025 | 2025-03-31 | 26.8M | 1.1M | +4.39% |
| Q4 2024 | 2024-12-31 | 26.7M | 1.0M | +3.97% |
| Q3 2024 | 2024-09-30 | 25.8M | 177,808 | +0.69% |
| Q2 2024 | 2024-06-30 | 25.7M | 183,808 | +0.72% |
| Q1 2024 | 2024-03-31 | 25.7M | 186,184 | +0.73% |
| Q4 2023 | 2023-12-31 | 25.7M | 334,943 | +1.32% |
| Q3 2023 | 2023-09-30 | 25.7M | 361,359 | +1.43% |
| Q2 2023 | 2023-06-30 | 25.6M | 289,957 | +1.15% |
| Q1 2023 | 2023-03-31 | 25.5M | 878,374 | +3.57% |
| Q4 2022 | 2022-12-31 | 25.4M | 727,115 | +2.95% |
| Q3 2022 | 2022-09-30 | 25.3M | 690,862 | +2.81% |
| Q2 2022 | 2022-06-30 | 25.3M | 671,862 | +2.73% |
| Q1 2022 | 2022-03-31 | 24.6M | 143,388 | +0.59% |
| Q4 2021 | 2021-12-31 | 24.6M | 313,196 | +1.29% |
| Q3 2021 | 2021-09-30 | 24.6M | 3.6M | +17.24% |
| Q2 2021 | 2021-06-30 | 24.6M | 3.6M | +17.39% |
| Q1 2021 | 2021-03-31 | 24.5M | 3.7M | +17.92% |
| Q4 2020 | 2020-12-31 | 24.3M | 6.4M | +36.00% |
| Q3 2020 | 2020-09-30 | 21.0M | 3.2M | +17.87% |
| Q2 2020 | 2020-06-30 | 21.0M | 3.2M | +17.98% |
| Q1 2020 | 2020-03-31 | 20.8M | 3.1M | +17.78% |
| Q4 2019 | 2019-12-31 | 17.9M | 269,558 | +1.53% |
| Q3 2019 | 2019-09-30 | 17.8M | 11.6M | +186.34% |
| Q2 2019 | 2019-06-30 | 17.8M | 11.8M | +196.05% |
| Q1 2019 | 2019-03-31 | 17.6M | — | — |
| Q4 2018 | 2018-12-31 | 17.6M | — | — |
| Q3 2018 | 2018-09-30 | 6.2M | — | — |
| Q4 2017 | 2017-12-31 | 6.0M | — | — |
Eton Pharmaceuticals shares outstanding trends
Over the last five reported fiscal years, Eton Pharmaceuticals's shares outstanding moved from 24.3M to 27.0M, a change of 2.7M. The latest reported quarter, Q2 2026, shows 28.3M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Eton Pharmaceuticals filings at SEC.gov ↗